Improving Cancer Drug Delivery with Computer Simulations
Computational model of targeted drug delivery
This project is creating computer models to help design better nanoparticle treatments for people with cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-11123253 on NIH RePORTER |
What this research studies
Many new drug delivery methods for cancer don't work well in human trials, partly because our current animal models aren't always enough. This project aims to build advanced computer models that can predict how well nanoparticles deliver drugs to tumors in a very detailed way. By using 3-D imaging of tumors to gather information, these models can simulate drug delivery and help scientists design more effective cancer therapies. This approach could lead to more efficient and successful nanoparticle-based treatments for cancer.
Who could benefit from this research
Good fit: This foundational work is for patients with cancer who may benefit from improved drug delivery methods in the future.
Not a fit: Patients seeking immediate treatment options would not directly benefit from this early-stage computational modeling work.
Why it matters
Potential benefit: If successful, this work could lead to more effective and targeted nanoparticle-based drug therapies for various cancers.
How similar studies have performed: While preliminary studies show the model's accuracy, the systematic design of nanoparticles using such comprehensive computational models is a novel approach to address current limitations.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Haemmerich, Dieter — Medical University of South Carolina
- Study coordinator: Haemmerich, Dieter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.